PDCD1 and lymphoma: The first trials with PD-1 pathway-blocking drugs highlighted their effectiveness in certain lymphomas, especially classical Hodgkin’s lymphoma (cHL), which harbour an intrinsic susceptibility to PD-1 blockade [98,99].